The challenge of developing a herpes simplex virus 2 vaccine.
about
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenAn attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challengePan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Prospects and perspectives for development of a vaccine against herpes simplex virus infections.Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity.Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human seraHerpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responsesEx vivo 2D and 3D HSV-2 infection model using human normal vaginal epithelial cells.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Animal models of herpes simplex virus immunity and pathogenesis.Periodontal herpesviruses: prevalence, pathogenicity, systemic risk.Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease.Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.A vaccine to prevent cervical cancer: academic and industrial collaboration and a Lasker award.
P2860
Q33663463-1212CA0F-D56F-4677-906C-C9A98F28584EQ33916162-B2E4863B-5D66-46EF-BE6D-2F98FBC198ABQ34350019-37A1CDB0-507D-4A9A-9A7C-47AE10F03171Q34414463-1835E8C6-B195-4827-901F-251809851BCCQ34431547-9B09EA46-9927-4235-8C10-12828B77954EQ34949279-85F8E941-8931-4888-8D67-BFA419C85A79Q36553837-AF356259-25B0-4755-AE11-DAF089CA0940Q36700993-A9B945D7-BC5C-494E-A6CA-1C938FBBF937Q36824210-9A6FA81A-C684-4699-8BE8-553F12497C6DQ37305004-BDB1E757-6830-47DF-AAE9-A1284CBBE1EDQ37716535-AFE30D54-ECE2-4B11-9EB8-56540D6BA0FCQ38212516-6BB6B40C-59DA-4E70-AA61-A6F931BBAC59Q38227257-97DED067-C143-4EBA-AFFF-32194BFABF86Q38260862-C789C3B9-37AA-484C-BEE2-FC1456BC0CCDQ38267269-7A5B06BC-FD43-43BA-99EA-0D19CDDD2B06Q38562419-FAF9BB56-910A-4AAD-B072-2BC9F354CA63Q38692329-FFBCF428-DAC7-4331-8ECB-E365527D3B44Q40223016-C0E8F6BC-384C-4EC5-8BA7-5B9EA8471C6AQ40443062-7DF1ACD2-A66D-4CB8-B51F-F0E6C0A08B73Q50315906-8009ED7F-7ABC-43AD-9800-5B7873D85FDF
P2860
The challenge of developing a herpes simplex virus 2 vaccine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The challenge of developing a herpes simplex virus 2 vaccine.
@ast
The challenge of developing a herpes simplex virus 2 vaccine.
@en
type
label
The challenge of developing a herpes simplex virus 2 vaccine.
@ast
The challenge of developing a herpes simplex virus 2 vaccine.
@en
prefLabel
The challenge of developing a herpes simplex virus 2 vaccine.
@ast
The challenge of developing a herpes simplex virus 2 vaccine.
@en
P2860
P356
P1476
The challenge of developing a herpes simplex virus 2 vaccine.
@en
P2093
Jeffrey I Cohen
Lesia K Dropulic
P2860
P304
P356
10.1586/ERV.12.129
P577
2012-12-01T00:00:00Z